Skip to main content
Terug
MDGL logo

Madrigal Pharmaceuticals, Inc.

Datakwaliteit: 100%
MDGL
NASDAQ Healthcare Biotechnology
€ 445,04
▼ € 2,68 (-0,60%)
Marktkapitalisatie: 10,21B
Dagbereik
€ 438,42 € 449,14
52-Weeksbereik
€ 265,00 € 615,00
Volume
197.756
50D / 200D Gem.
€ 468,57 / € 437,29
Vorige Slotkoers
€ 447,72

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -35,4 0,3
P/B 16,9 2,9
ROE % -42,5 3,7
Net Margin % -30,1 3,8
Rev Growth 5Y % 10,0
D/E 0,6 0,2

Koersdoel Analisten

Hold
€ 705,67 +58.6%
Low: € 527,00 High: € 964,00
Forward WPA
-€ 4,49
Omzet Sch.
1,5 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 70,33
€ 59,58 – € 79,31
4,9 B 4
FY2029 € 49,53
€ 41,96 – € 55,85
3,9 B 4
FY2028 € 31,37
€ 16,07 – € 49,15
3 B 11

Belangrijkste Punten

Negative free cash flow of -190,02M
Capital efficient — spends only 0,05% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)432,05%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-42,49%
ROIC-23,52%
Net Margin-30,08%
Op. Margin-31,31%

Veiligheid

Debt / Equity
0,59
Current Ratio4,01
Interest Coverage-13,45

Waardering

P/E Ratio
-35,41
P/B Ratio16,94
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 432,05% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 958,40M Net Income (TTM) -288,28M
ROE -42,49% ROA -22,89%
Gross Margin 94,14% Operating Margin -31,31%
Net Margin -30,08% Free Cash Flow (TTM) -190,02M
ROIC -23,52% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,59 Current Ratio 4,01
Interest Coverage -13,45 Dividend Yield 0,00%
Valuation
P/E Ratio -35,41 P/B Ratio 16,94
P/S Ratio 10,65 PEG Ratio 1,10
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 10,21B Enterprise Value 10,36B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 958,40M 180,13M 0,0 0,0 0,0
Net Income -288,28M -465,89M -373,63M -295,35M -241,85M
EPS (Diluted) -12,85 -21,90 -19,99 -17,23 -14,63
Gross Profit 902,26M 173,90M 0,0 0,0 0,0
Operating Income -300,10M -497,88M -380,50M -293,57M -242,48M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,26B 1,04B 640,55M 362,57M 273,33M
Total Liabilities 656,90M 287,86M 235,21M 165,18M 77,23M
Shareholders' Equity 602,69M 754,38M 405,33M 197,39M 196,11M
Total Debt 354,36M 119,57M 117,19M 49,89M 797.000,0
Cash & Equivalents 198,69M 100,02M 99,92M 331,55M 36,27M
Current Assets 1,25B 1,03B 637,28M 361,37M 271,68M
Current Liabilities 310,29M 169,28M 118,55M 115,89M 76,84M